The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses key considerations in frontline Hodgkin lymphoma management. He highlights the high rates of long-term remission achieved with newer combinations such as brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) and nivolumab plus AVD, emphasizing the importance of balancing efficacy with long-term toxicity. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
